Analysts Anticipate Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) to Post -$1.14 Earnings Per Share

Equities research analysts expect Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) to announce earnings per share of ($1.14) for the current quarter, Zacks reports. Zero analysts have made estimates for Zentalis Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.93) and the lowest estimate coming in at ($1.29). Zentalis Pharmaceuticals reported earnings per share of ($0.78) in the same quarter last year, which would indicate a negative year-over-year growth rate of 46.2%. The business is expected to announce its next earnings results on Thursday, August 12th.

On average, analysts expect that Zentalis Pharmaceuticals will report full year earnings of ($4.61) per share for the current fiscal year, with EPS estimates ranging from ($5.41) to ($3.70). For the next financial year, analysts forecast that the business will report earnings of ($4.75) per share, with EPS estimates ranging from ($5.74) to ($3.22). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Zentalis Pharmaceuticals.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Monday, May 17th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.27).

Several equities analysts recently weighed in on ZNTL shares. SVB Leerink lifted their target price on shares of Zentalis Pharmaceuticals from $60.00 to $64.00 and gave the company an “outperform” rating in a report on Monday, April 19th. Zacks Investment Research raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday. UBS Group assumed coverage on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 20th. They issued a “buy” rating and a $91.00 target price for the company. Finally, HC Wainwright boosted their target price on shares of Zentalis Pharmaceuticals from $65.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, May 19th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Zentalis Pharmaceuticals has a consensus rating of “Buy” and an average target price of $69.83.

Shares of NASDAQ:ZNTL traded down $0.84 during midday trading on Friday, hitting $49.75. 485 shares of the company’s stock traded hands, compared to its average volume of 359,127. The firm has a fifty day moving average price of $52.91. Zentalis Pharmaceuticals has a twelve month low of $25.41 and a twelve month high of $62.79.

In other Zentalis Pharmaceuticals news, CEO Anthony Y. Sun sold 25,045 shares of the business’s stock in a transaction dated Tuesday, July 6th. The shares were sold at an average price of $46.90, for a total transaction of $1,174,610.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Anthony Y. Sun sold 26,794 shares of the company’s stock in a transaction that occurred on Monday, May 3rd. The stock was sold at an average price of $59.32, for a total transaction of $1,589,420.08. Following the completion of the sale, the chief executive officer now directly owns 1,474,161 shares of the company’s stock, valued at $87,447,230.52. The disclosure for this sale can be found here. Insiders have sold a total of 206,032 shares of company stock valued at $10,798,251 over the last three months. 21.00% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the company. Wells Fargo & Company MN lifted its stake in shares of Zentalis Pharmaceuticals by 99.6% in the 4th quarter. Wells Fargo & Company MN now owns 16,865 shares of the company’s stock worth $876,000 after acquiring an additional 8,415 shares during the period. Northern Trust Corp lifted its stake in shares of Zentalis Pharmaceuticals by 0.3% in the 1st quarter. Northern Trust Corp now owns 283,323 shares of the company’s stock worth $12,293,000 after acquiring an additional 881 shares during the period. UBS Asset Management Americas Inc. lifted its stake in shares of Zentalis Pharmaceuticals by 53.0% in the 1st quarter. UBS Asset Management Americas Inc. now owns 17,600 shares of the company’s stock worth $764,000 after acquiring an additional 6,100 shares during the period. Silverarc Capital Management LLC acquired a new stake in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $519,000. Finally, Virtu Financial LLC bought a new stake in Zentalis Pharmaceuticals during the fourth quarter worth approximately $371,000. 87.82% of the stock is owned by institutional investors.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer.

Recommended Story: How much can an individual set aside as a catch-up contribution?

Get a free copy of the Zacks research report on Zentalis Pharmaceuticals (ZNTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.